Johnson & Johnson should ready itself for a flood of new lawsuits after a jury ordered the company to pay $4.69 billion to 22 women who blamed their ovarian cancer on asbestos in its talc products, legal experts said. There are already more than 9,000 suits claiming talc-based baby powder causes ovarian and asbestos-specific cancers. That number is likely to jump in the wake of the Missouri jury\u2019s decision, said Elizabeth Burch, a University of Georgia law professor who teaches about mass-tort law. It\u2019s not just because of the size of the award - the biggest of 2018 and the sixth-largest product-defect verdict in U.S. history - but the evidence that was presented at trial: internal documents that show company officials were aware for more than 30 years there were at least trace amounts of asbestos found in different batches of the talc used in its baby powder. \u201cThe floodgates were already open on this issue, but this verdict breaks the dam,\u201d Burch said in an interview Friday. \u201cIt\u2019s going to be difficult for J&J to say\u201d going forward there\u2019s no asbestos in its talc products, she added. While J&J has fought suits blaming cancer on its iconic baby powder in the past, investors haven\u2019t reacted to courtroom losses. Given the size of the award and that it came out of the first trial test of claims of an asbestos-ovarian cancer link, investors are likely to increase their focus on the talc cases on the heels of the large award for the plaintiffs, according to Credit Suisse analyst Vamil Divan, who has an outperform rating on the company\u2019s shares. Divan said he is confident J&J can absorb \u201ceven relatively large payments\u201d to resolve the cases. Even so, shares fell as much 1.9 percent on Friday in New York trading the morning after the verdict. Appeal Planned The women contend they were exposed to asbestos by inhaling the powder or using it on their genitals. More than 20,000 ovarian cancer cases are reported annually in the U.S., according to the National Cancer Institute. More of those cases are likely to be translated into suits given the headline-grabbing nature of the verdict, Burch said. The company issued a statement Thursday faulting the jurisdiction and pointing out that many of the 22 women weren\u2019t from Missouri, so they shouldn\u2019t have been allowed to join the St. Louis case. J&J said it plans to appeal. The products don\u2019t contain asbestos and don\u2019t cause ovarian cancer, J&J spokeswoman Carol Goodrich said, predicting a reversal. \u201cThe multiple errors present in this trial were worse than those in the prior trials which have been reversed.\u201d J&J \u201cwill appeal till the cows come home, or until all the plaintiffs die,\u201d plaintiffs\u2019 lawyer Mark Lanier said Thursday. J&J should pull its talc-based products from the market or \u201cmark it with a serious warning,\u201d he said. In May, a California jury asked a judge in another talc case if it could force J&J to add a warning to its white baby-powder bottles that the product may contain asbestos. The judge said that wasn\u2019t in their power. \u201cThis was a new theory and the jury lined up behind it,\u201d said Jean Eggen, a Widener University law professor who teaches about mass-tort cases. \u201cThat may be a harbinger of things to come and there are many more ovarian cancer cases than asbestos cases tied to the powder.\u201d The verdict could spur J&J to start thinking about settling the talc cases, Holly Froum, a Bloomberg Intelligence analyst, noted in a report to clients. She says the settlement value of the cases could reach as much as $20 billion. But J&J has traditionally been loathe to settle big cases without allowing the appellate courts to have their say. That\u2019s helped in St. Louis, where it\u2019s faced multiple trials over ovarian cancer claims. It lost four of the first five to go to trial, overturned two on jurisdictional grounds that a U.S. Supreme Court ruling barred the women from suing somewhere where they have no ties. The other two are on appeal on the same grounds. The company has also had a better record with judges than juries in the ovarian cancer cases. A separate plaintiffs\u2019 award, for $417 million by a Los Angeles jury in August, was reversed by the trial judge who decided evidence didn\u2019t support the verdict. A New Jersey judge in 2016 stalled lawsuits in that state by tossing two cases set for trial, also finding a lack of scientific evidence. The case is Ingham v. Johnson & Johnson, 1522-CC10417, Circuit Court, City of St. Louis, Missouri.